About
About Adicet Bio, Inc
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin's lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.
Visit company website
5 years, 5 months ago
Adicet Bio, Inc is currently in a long term downtrend where the price is trading 29.6% below its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.3.
Adicet Bio, Inc's total revenue rose by 174.8% to $5M since the same quarter in the previous year.
Its net income has dropped by 36.2% to $-9M since the same quarter in the previous year.
Finally, its free cash flow fell by 77.6% to $-14M since the same quarter in the previous year.
Based on the above factors, Adicet Bio, Inc gets an overall score of 2/5.